Dallas-based Forte Biosciences, Inc. (Nasdaq: FBRX) has reported statistically significant repigmentation data from a Phase Ib double-blind, placebo-controlled study of FB102 in vitiligo — the first placebo-controlled evidence of efficacy for the anti-CD122 monoclonal antibody in a skin depigmentation disorder. The results provide mechanistic support for FB102's broader autoimmune ambitions, while the vitiligo treatment landscape is rapidly evolving as systemic therapies enter the picture, .
In the protocol-defined efficacy-evaluable population, FB102 achieved a 29.6% mean improvement in the Facial Vitiligo Area Scoring Index (FVASI) from baseline at week 24, compared with 7.9% for placebo, a placebo-adjusted benefit of 21.7% (p=0.020). The trial enrolled 43 subjects randomized 3:1, with 32 on FB102 across two dosing cohorts and 11 on placebo. Statistically significant separation from placebo was observed as early as day 64 (p=0.023), and improvement continued to accumulate for 12 weeks after the treatment period ended — patients gained an additional eight percentage points in FVASI improvement between week 12 and week 24. Among subjects with greater baseline disease burden (FVASI ≥0.75), the mean improvement reached 43.2% versus 0.5% for placebo (p=0.006), with 58.8% achieving FVASI50 and 23.5% achieving FVASI75. No subjects on FB102 worsened over 24 weeks; 27% of placebo subjects did. All adverse events were mild to moderate.
The post-treatment improvement trajectory is analytically notable. Repigmentation in vitiligo is inherently slow — melanocyte regeneration from follicular reservoirs takes time — but the continued gains after dosing stopped potentially suggest a durable immunological effect rather than simple symptomatic suppression. FB102 targets CD122, the shared beta subunit of the IL-2 and IL-15 receptors, simultaneously modulating both cytokine pathways while, according to the company, preserving regulatory T cells. This distinguishes it mechanistically from pure IL-15 blockade.
The competitive context is increasingly crowded. Incyte's Opzelura (ruxolitinib) cream remains the only approved pharmacological therapy for vitiligo, but its label restricts use to up to 10% body surface area, leaving patients with extensive disease without a systemic option. AbbVie has submitted regulatory applications to the US FDA and the European Medicines Agency for upadacitinib (Rinvoq), an oral JAK inhibitor that met co-primary endpoints in Phase III Viti-Up studies at week 48. Teva Pharmaceutical Industries' TEV-'408, an anti-IL-15 antibody designed for quarterly dosing, recently reported Phase Ib data showing 42% F-VASI50 at week 24 from just two doses, and is advancing into Phase IIb. FB102's CD122 mechanism spans both IL-2 and IL-15 signaling, which Forte argues may offer broader pathway modulation than IL-15 blockade alone, though cross-trial comparisons across these early-stage programs remain limited by different patient populations, endpoints, and study designs.